Immunic, Inc. (IMUX)
Immunic secures US patent protection for vidofludimus calcium in dose strengths in progressive MS
Immunic Inc (NASDAQ:IMUX) announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) covering dose strengths of its lead asset, vidofludimus calcium (IMU-838), for the treatment of progressive multiple sclerosis (PMS). The patent, tied to application 18/529,946, protects daily dosing of about 10 mg to 45 mg of vidofludimus calcium, including other salt and free acid forms, for patients with primary progressive multiple sclerosis (PPMS) and secondary progressive multiple sclerosis (SPMS).
Immunic reports promising Phase 2 data for lead drug candidate in progressive MS - ICYMI
Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt talked with Proactive about the company's second quarter highlights, with a particular focus on clinical progress in its multiple sclerosis (MS) programs. The headline development was the promising results from the Phase 2 CALLIPER trial of vidofludimus calcium, Immunic's lead asset.
Immunic advances MS drug program with Phase 3 trials fully enrolled
Immunic Inc (NASDAQ:IMUX) said on Thursday it has fully enrolled its twin Phase 3 ENSURE trials for vidofludimus calcium, positioning the company for a major data readout by end-2026 in relapsing multiple sclerosis (RMS). The oral therapy, which activates the Nurr1 nuclear receptor, has shown neuroprotective, anti-inflammatory, and anti-viral properties.
Immunic CEO discusses Phase 2 multiple sclerosis study success - ICYMI
Immunic Inc (NASDAQ:IMUX) CEO Dr Daniel Vitt talked with Proactive about new positive data from the company's phase 2 EMPhASIS trial of vidofludimus calcium in relapsing-remitting multiple sclerosis (RRMS). Proactive: Hello you're watching Proactive, I'm joined by Immunic CEO Dr Daniel Vitt.
Immunic reveals long-term data supporting potential of MS drug vidofludimus calcium
Immunic Inc (NASDAQ:IMUX) released new long-term data from an ongoing study showing that its experimental drug, vidofludimus calcium, continues to help patients with relapsing-remitting multiple sclerosis (RRMS) over time. The biotech company said 92.3% of patients remained free of 12-week confirmed disability worsening (CDW) and 92.7% free of 24-week CDW at week 144, based on data representing roughly 952 cumulative treatment years.
Immunic showcases MS drug data at BIO International Convention in Boston - ICYMI
Immunic Inc (NASDAQ:IMUX) chief operating officer Jason Tardio talked with Proactive about the company's participation at the BIO International Convention in Boston and recent clinical developments. Tardio highlighted Immunic's ongoing business development efforts, particularly around its lead asset, vidofludimus calcium, aimed at treating multiple sclerosis (MS).
Immunic Post-Readout: Reiterating Strong Buy As Big Drop Appears Unwarranted
Immunic, Inc.'s CALLIPER study showed vidofludimus calcium reduced disability progression by 30% in PPMS patients, despite modest MRI results, suggesting strong neuroprotective effects. IMUX stock's significant drop appears to be an overreaction, given the positive disability progression data and clean safety profile. The company plans a Phase 3 trial focusing on confirmed disability progression, a key regulatory endpoint, to confirm these promising results.
Immunic completes Phase 3 multiple sclerosis trial enrollment - ICYMI
Immunic Inc (NASDAQ:IMUX)'s chief medical officer Dr Andreas Muehler talked with Proactive about the successful completion of patient enrollment for its Phase 3 ENSURE program targeting relapsing multiple sclerosis (MS). The ENSURE-1 and ENSURE-2 trials, described as "twin studies," have collectively enrolled over 2,000 patients across 15 countries.
Immunic completes patient enrollment in Phase 3 relapsing multiple sclerosis trials
Immunic Inc (NASDAQ:IMUX) has announced the completion of enrollment for both phase 3 ENSURE trials of its lead asset, vidofludimus calcium (IMU-838), in relapsing multiple sclerosis (RMS). The ENSURE program includes two identical, multicenter, randomized, double-blind phase 3 trials, ENSURE-1 and ENSURE-2, designed to assess the efficacy, safety, and tolerability of vidofludimus calcium compared to placebo in patients with RMS.
Immunic raises $65M in public offering to fund clinical trials
Immunic Inc (NASDAQ:IMUX), a biotechnology firm focused on developing oral therapies for chronic inflammatory and autoimmune diseases, on Tuesday closed a previously announced underwritten public offering, raising approximately $65 million in initial proceeds. The offering consisted of pre-funded warrants, Series A warrants, and Series B warrants to purchase shares of common stock or additional pre-funded warrants.
Immunic unveils pricing of $65M underwritten public offering
Immunic Inc (NASDAQ:IMUX) has announced the pricing of an oversubscribed underwritten public offering that is expected to generate approximately $65 million in gross proceeds, which the company plans to use to support its clinical trials, operations, and other general corporate purposes. The offering consists of pre-funded warrants, Series A warrants, and Series B warrants sold together at a combined public offering price of $0.7499.
Immunic reports reduced disability worsening in progressive multiple sclerosis trial
Immunic Inc (NASDAQ:IMUX) has reported promising results from its Phase 2 CALLIPER trial of vidofludimus calcium, which showed a 30% reduction in the risk of 24-week confirmed disability worsening in patients with primary progressive multiple sclerosis (PPMS) compared to placebo. The study enrolled 467 patients with progressive multiple sclerosis (PMS), including subpopulations with PPMS and non-active secondary progressive multiple sclerosis.
